SCHEMBL11965791

SCHEMBL11965791

C[n+]1c(/C=C2\C=C(N3CCOCCOCCN(C4=C/C(=C\c5sc6ccccc6[n+]5C)c5ccccc5N4c4ccccc4)CCOCCOCC3)N(c3ccccc3)c3ccccc32)sc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 1/20 0.40
▸ SNCA P37840 2/20 0.39
▸ MAPT P10636 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ NR2F2 P24468 1/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ ADRB2 P07550 2/20 0.33
▸ ACHE P22303 4/20 0.32
▸ BCHE P06276 3/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ ADRB1 P08588 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11917722 0.92 SNCA (0.40) HCRTR1SNCAMAPTNPC1HTT
SCHEMBL11917741 0.88 SNCA (0.37) SNCAMAPTNPC1HTTRAB9A
SCHEMBL15290725 0.83 SNCA (0.34) HCRTR1SNCAMAPTNPC1HTT
SCHEMBL11917744 0.80 SNCA (0.38) SNCAMAPTNPC1HTTRAB9A
SCHEMBL11920298 0.80 MAPT (0.43) SNCAMAPTNPC1HTTRAB9A
SCHEMBL12889794 0.79 SNCA (0.32) SNCA
SCHEMBL13223484 0.79 ADRB2 (0.41) SNCAMAPTNPC1HTTRAB9A
SCHEMBL11917742 0.77 MAPT (0.38) SNCAMAPTNPC1HTTRAB9A
SCHEMBL12595096 0.77 MAPT (0.38) SNCAMAPTNPC1HTTRAB9A
SCHEMBL14089536 0.76 NPC1 (0.32) SNCANPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242251-B2 Unsymmetrical cyanine dimer compounds and their application Life Technologies Corporation (US) 2012-08-14 — — US disclosed
US-20110124085-A1 UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION Life Technologies Corporation (US) 2011-05-26 — — US disclosed
US-7888136-B2 Comprises benzazolium, pyridinium, or quinolinium connected by methine bridge; reporter molecules for detection of RNA in presence of DNA; solid phase synthesis; kits Life Technologies Corporation (US) 2011-02-15 — — US disclosed
US-20080199875-A1 UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION INVITROGEN CORPORATION (US) 2008-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080199875-A1 UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION NSUN2, NSUN3, TRDMT1 HCRTR1 2585/4885SNCA 3350/4885MAPT 4304/4885
US-20110124085-A1 UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION NSUN2, NSUN3, TRDMT1 HCRTR1 2585/4885SNCA 3350/4885MAPT 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback